Notícias

No dia 12 de abril, a ABIFINA participou de reunião a convite da Segunda Diretoria da Anvisa (DIRE2) cujo tema...

No dia 13 de abril, a ABIFINA participou da 2ª reunião ordinária do Conselho Nacional de Combate à Pirataria (CNCP),...

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the coronavirus disease-19 (COVID-19) pandemic, was identified in late...

Summary

Background

We previously reported the efficacy of the adjuvanted-protein COVID-19 vaccine candidate S-Trimer (SCB-2019) in adults who showed no...

Abstract

BACKGROUND

Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan–human-coronavirus...

Abstract

Cases of deaths due to COVID-19 (COrona VIrus Disease-19) infection are increasing gradually worldwide. Immense research is ongoing to...

Summary

Background

We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases...

Since the identification of the novel coronavirus (SARS-CoV-2), the scientific community has made a huge effort to understand the virus...

Abstract

BACKGROUND

With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2...

Evento online em 14 de abril (Dia Mundial da Doença de Chagas) debaterá políticas públicas e cuidados essenciais aos pacientes  ...

We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases in Ontario,...

Multiple vaccine candidates against COVID-19 are currently being evaluated. We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2...